|Bid||8.30 x 2200|
|Ask||8.40 x 1100|
|Day's range||8.25 - 8.78|
|52-week range||7.78 - 21.82|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2021 - 06 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.11|
At this time, I would like to welcome everyone to the Karyopharm Therapeutics' First Quarter 2021 Financial Results Conference Call. This is Ian Karp and today, in addition to both Michael Kauffman and Richard Paulson, I'm also joined by Mr. Mike Mason, our Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; and Mr. Stephen Mitchener, our Chief Business Officer.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.00% and -12.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).